Medically reviewed by Danielle Weiss, MD Diabetic macular edema (DME) is a leading cause of vision loss in people with ...

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic ...

Managing diabetes effectively helps control the risk of health complications associated with it and also improves quality of ...

Unity Biotechnology has reported topline outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic macular oedema. The multi-centre trial is designed to evaluate the ...

Diabetes can influence more than just your blood sugar levels It can also affect multiple organs in the body including the ...

The investigators conducted a prospective interventional study to determine the therapeutic anatomic and functional effects ...

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...

In October, after almost a decade of work, Google licensed its artificial intelligence (AI) model for detecting the eye disease diabetic retinopathy to three health-care technology companies ...

The left eye also showed significant diabetic macular oedema, for which intravitreal injections were administered. As a result, a significant amount of her vision was salvaged. According to Dr ...